These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24077529)

  • 1. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.
    Carotenuto A; Cipolletta E; Gomez-Monterrey I; Sala M; Vernieri E; Limatola A; Bertamino A; Musella S; Sorriento D; Grieco P; Trimarco B; Novellino E; Iaccarino G; Campiglia P
    Eur J Med Chem; 2013 Nov; 69():384-92. PubMed ID: 24077529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.
    Guccione M; Ettari R; Taliani S; Da Settimo F; Zappalà M; Grasso S
    J Med Chem; 2016 Oct; 59(20):9277-9294. PubMed ID: 27362616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
    Okawa T; Aramaki Y; Yamamoto M; Kobayashi T; Fukumoto S; Toyoda Y; Henta T; Hata A; Ikeda S; Kaneko M; Hoffman ID; Sang BC; Zou H; Kawamoto T
    J Med Chem; 2017 Aug; 60(16):6942-6990. PubMed ID: 28699740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR study and conformational analysis of a series of novel peptide G protein-coupled receptor kinase 2 inhibitors.
    Gomez-Monterrey I; Carotenuto A; Cipolletta E; Sala M; Vernieri E; Limatola A; Bertamino A; Musella S; Grieco P; Trimarco B; Novellino E; Iaccarino G; Campiglia P
    Biopolymers; 2014 Jan; 101(1):121-8. PubMed ID: 23733420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
    Xu G; Gaul MD; Liu Z; DesJarlais RL; Qi J; Wang W; Krosky D; Petrounia I; Milligan CM; Hermans A; Lu HR; Huang DZ; Xu JZ; Spurlino JC
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127602. PubMed ID: 33038544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors.
    Waldschmidt HV; Bouley R; Kirchhoff PD; Lee P; Tesmer JJG; Larsen SD
    Bioorg Med Chem Lett; 2018 May; 28(9):1507-1515. PubMed ID: 29627263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of inhibitors of the RGS homology domain of GRK2 by docking-based virtual screening.
    Echeverría E; Velez Rueda AJ; Cabrera M; Juritz E; Burghi V; Fabián L; Davio C; Lorenzano Menna P; Fernández NC
    Life Sci; 2019 Dec; 239():116872. PubMed ID: 31525427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.
    Cho SY; Lee BH; Jung H; Yun CS; Ha JD; Kim HR; Chae CH; Lee JH; Seo HW; Oh KS
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6711-6. PubMed ID: 24210504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead identification of novel and selective TYK2 inhibitors.
    Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S
    Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1.
    Keretsu S; Bhujbal SP; Joo Cho S
    Sci Rep; 2019 Sep; 9(1):13053. PubMed ID: 31506468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2.
    Han C; Li Y; Wang Y; Cui D; Luo T; Zhang Y; Ma Y; Wei W
    Cell Physiol Biochem; 2018; 51(2):729-745. PubMed ID: 30463058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of substrates and inhibitors of G protein-coupled receptor kinase 2 (GRK2) based on its phosphorylation reaction.
    Kang JH; Toita R; Kawano T; Murata M; Asai D
    Amino Acids; 2020 Jul; 52(6-7):863-870. PubMed ID: 32577910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
    Waldschmidt HV; Homan KT; Cato MC; Cruz-Rodríguez O; Cannavo A; Wilson MW; Song J; Cheung JY; Koch WJ; Tesmer JJ; Larsen SD
    J Med Chem; 2017 Apr; 60(7):3052-3069. PubMed ID: 28323425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101.
    Yu Q; Gratzke C; Wang Y; Herlemann A; Strittmatter F; Rutz B; Stief CG; Hennenberg M
    Eur J Pharmacol; 2018 Jul; 831():9-19. PubMed ID: 29698717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.
    Thal DM; Yeow RY; Schoenau C; Huber J; Tesmer JJ
    Mol Pharmacol; 2011 Aug; 80(2):294-303. PubMed ID: 21596927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRK2 inhibition in heart failure: something old, something new.
    Lymperopoulos A; Rengo G; Koch WJ
    Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway.
    Fu X; Koller S; Abd Alla J; Quitterer U
    J Biol Chem; 2013 Mar; 288(11):7738-7755. PubMed ID: 23362259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel inhibitors of phosphorylation independent activity of GRK2 modulate cAMP signaling.
    Echeverría E; Ripoll S; Fabián L; Shayo C; Monczor F; Fernández NC
    Pharmacol Res Perspect; 2022 Apr; 10(2):e00913. PubMed ID: 35184416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tonic inhibition by G protein-coupled receptor kinase 2 of Akt/endothelial nitric-oxide synthase signaling in human vascular endothelial cells under conditions of hyperglycemia with high insulin levels.
    Taguchi K; Sakata K; Ohashi W; Imaizumi T; Imura J; Hattori Y
    J Pharmacol Exp Ther; 2014 May; 349(2):199-208. PubMed ID: 24570070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors.
    Kassack MU; Högger P; Gschwend DA; Kameyama K; Haga T; Graul RC; Sadée W
    AAPS PharmSci; 2000; 2(1):E2. PubMed ID: 11741218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.